Evaluation of Comprehensive Geriatric Assessment and Laboratory Biomarkers in Elderly Patients With Multiple Myeloma

Overseen By Clinical Trials Referral Office

Age: 65+

Sex: Any

Trial Phase: Academic

Sponsor: Mayo Clinic

No Placebo Group All trial participants will receive the active study treatment (no placebo)

Compensation: Varies

Number of Visits: Unknown

100 Participants Needed

Trial Summary

What is the purpose of this trial?

This study evaluates the association between a comprehensive geriatric assessment and laboratory biomarkers with the side effects of chemotherapy in older patients with multiple myeloma (MM). The comprehensive geriatric assessment is a tool that can help to determine how fit a patient is. It is composed of a series of questions and tests designed for older people to evaluate their physical function, mental status, mental health, nutritional status, social support, level of social activity, and the presence of other medical problems. In addition to geriatric assessment domains, laboratory biomarkers may provide information on physiologic dysfunction as a measure for evaluation of frailty in the cancer setting. This study will help researchers in the future by predicting which patients will have more side effects with chemotherapy based on their comprehensive geriatric assessment and laboratory biomarkers, which will allow adjustments to treatment in older adult patients with MM.

Research Team

Shaji K. Kumar, MD

Principal Investigator

Mayo Clinic in Rochester

Eligibility Criteria

Inclusion Criteria

Newly diagnosed or have received 1 prior line of treatment

Planned to start a new treatment for MM within 30 days

Transplant eligible or ineligible

Treatment Details

Participant Groups

Group I: Observational (Surveys, cGA, blood sample, EHR review) Experimental Treatment 4 Interventions

Patients complete surveys and undergo cGA, blood sample collection, and EHR review on study.

Who Is Running the Clinical Trial?

Mayo Clinic

Lead Sponsor

Trials

3,427

Recruited

3,221,000+